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Abstract
Wheat products make a substantial contribution to the dietary intake of many people worldwide. Despite the many
beneficial aspects of consuming wheat products, it is also responsible for several diseases such as celiac disease
(CD), wheat allergy, and nonceliac gluten sensitivity (NCGS). CD and irritable bowel syndrome (IBS) patients have
similar gastrointestinal symptoms, which can result in CD patients being misdiagnosed as having IBS. Therefore,
CD should be excluded in IBS patients. A considerable proportion of CD patients suffer from IBS symptoms despite
adherence to a gluten-free diet (GFD). The inflammation caused by gluten intake may not completely subside in
some CD patients. It is not clear that gluten triggers the symptoms in NCGS, but there is compelling evidence that
carbohydrates (fructans and galactans) in wheat does. It is likely that NCGS patients are a group of self-diagnosed
IBS patients who self-treat by adhering to a GFD.
Introduction
The three most important food grains worldwide are
wheat, maize, and rice [1]. However, the ability to
produce high yields of wheat under a broad range of
conditions, so that it can be cultivated successfully at
global latitudes from 67° N in Scandinavia to 45° S in
Argentina, renders it particularly useful as a food source
[1]. The nutritional needs following the two world wars
and the exponential growth of the world population re-
sulted in the global production and consumption of
wheat expanding hugely by the end of the twentieth cen-
tury [1–3]. Moreover, several countries in Asia have re-
duced their consumption of rice considerably during the
last years, probably in favor of wheat consumption [4]
[Hossain M. Food and Agriculture Organization of the
United Nation. 2004. www.fao.org/rice2004/en/e-001.htm]
(Table 1). The high consumption of wheat is not only at-
tributed to its adaptability and potential for high yields, but
also to its viscoelasticity, which allows it to be processed
into several food items such as bread, baked products, and
pastas [1]. Wheat and wheat-based products make substan-
tial contributions to the dietary intake of protein, dietary
fiber, minerals (especially iron, zinc, and selenium), vita-
mins, phytochemicals, and energy [1]. It has been estimated
that several billion people rely on wheat for a substantial
part of their diet [1].
White flour comprises about 80 % starch and 10 %
protein [1, 5]. The indigestible oligosaccharides such as
fructo-oligosaccharides and fructans constitute 13.4 % of
the dietary fiber in wheat [5, 6]. Moreover, wheat con-
tains a considerable amount of the indigestible oligosac-
charides galactans [6, 7]. Gluten constitutes 80 % of the
wheat proteins, and comprises two major groups: the
glutenins and the gliadins (prolines) [8, 9]. The glutenins
occur in two forms, the high- and low-molecular-weight
fractions [8–11], while the gliadins exist as three struc-
tural forms, α-, ω-, and γ-gliadins [8–11]. Glutenins and
gliadins undergo partial digestion in the upper gastro-
intestinal tract, resulting in the formation of various na-
tive peptide derivatives that are resistant to digestion by
the gastrointestinal proteases [12].
Despite the many beneficial aspects of consuming
wheat products, it can cause several diseases such as ce-
liac disease (CD), wheat allergy (WA), and nonceliac glu-
ten sensitivity (NCGS) [12, 13]. The prevalence rates of
CD, WA, and NCGS are estimated to be 0.5–2 % in the
Western population [14–23], 0.2–0.5 % in the European
population [24], and 0.55–6 % of the USA population
[11, 25], respectively. CD is an immunological response
to ingested gluten that results in small-intestine villous
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atrophy with increased intestinal permeability and mal-
absorption of nutrients [26]; WA is characterized by an
IgE-mediated response against various wheat compo-
nents that results in respiratory or gastrointestinal
symptoms [27]; and NCGS is characterized by both
gastrointestinal and extragastrointestinal symptoms
that are triggered by the ingestion of wheat products
(possibly due to the gluten content). These symptoms
improve after removing wheat products from the diet,
and relapse following a wheat challenge. The gastro-
intestinal symptoms in NCGS are abdominal pain,
diarrhea or constipation, nausea, and vomiting, and
the extragastrointestinal symptoms are headache,
musculoskeletal pain, brain fog, fatigue, and depres-
sion [28, 29]. NCGS is often perceived by the patients
themselves, leading to self-diagnosis and self-treatment.
Patients with irritable bowel syndrome (IBS), CD, and
the recently debated diagnosis of NCGS exhibit similar
gastrointestinal and extragastrointestinal symptoms [4,
30–37]. Application of symptom-based diagnosis criteria
such as the Rome III criteria could result in diagnosing
patients with CD or NCGS as having IBS. However, it
has been suggested that these three conditions overlap
[4, 12]. The aim of this review was to elucidate this pos-
sible overlapping of these three conditions and to find
out a way to separate them in everyday clinical practice.
IBS and CD
The connection between IBS and CD: is it a misdiagnosis
or an overlap?
As mentioned above, there is overlap in the symptoms
of IBS and CD. Since the diagnosis of IBS is based
mainly on symptom assessment using symptom criteria
such as the Rome III criteria, there is a risk of CD pa-
tients being misdiagnosed as having IBS. The situation is
complicated even further by the fact that the abdominal
symptoms in both IBS and CD patients are triggered by
the ingestion of wheat products. However, whereas this
is caused by gluten allergy in CD patients, it is attributed
in IBS patients to the long-sugar-polymer fructans in
wheat [38]. The prevalence of CD patients among IBS
patients who have been misdiagnosed using symptom
criteria for IBS has varied between studies from 0 to
31.8 %, but in most studies it seems to lie in the range
0.4–4.7 % [14, 23, 39–48]. Regardless of this variation in
the prevalence of CD patients who have been misdiag-
nosed with IBS between studies, it is a considerable
number that should not be disregarded. These findings
have led to the British Society of Gastroenterology
recommending that CD should be excluded in all pa-
tients referred with IBS [49], and the American College
of Gastroenterology have advised the exclusion of CD in
patients with diarrhea-predominant IBS and IBS with a
mixed bowel pattern [47]. Based on the international
guidelines, published data, and our own clinical experi-
ence, we believe that all referred IBS patients should be
tested for CD with serologic testing, including a combin-
ation of tissue transglutaminase (tTG) and deamidated
gliadin peptide (DGP) antibodies, which have demon-
strated a high sensitivity and specificity [50], and when
there is doubt, duodenal biopsy samples should be taken.
In our clinical experience, it is not uncommon for pa-
tients to test positive for tTG but negative for DGP, and
vice versa, making it necessary to perform both tests in
patients. This suggestion is supported by reports that
the time between CD symptom onset and correct med-
ical diagnosis is between 5.1 and 11.7 years [51, 52]. This
period is prolonged from an average of 7 years in CD pa-
tients with no prodromal IBS to 10 years in those with
prodromal IBS [53].
The reported prevalence of positivity to antigliadin
antibodies (AGA; IgG and IgA) without any confirm-
ation of positivity to tTG or DGP antibodies in the blood
of IBS patients has varied from 5 to 17 % [14, 44, 54] to
as high as about 50 % [55, 56]. AGA positivity has been
reported to have a good sensitivity, but a low specificity
for CD [57], and the serum of 12–15 % of healthy sub-
jects is positive for AGA [14, 44, 57, 58]. This raises an
interesting question: why would a healthy subject have
these antibodies to gliadin with no clinical implications?
One could speculate that mucosal damage and failure of
the mucosal barrier caused by acute or chronic alcohol
consumption [59], or by a bout of gastroenteritis, would
allow the immunogenic peptides resulting from the par-
tial digestion of glutamines and gliadins to enter the
lamina propria, where they could interact with immune
cells, resulting in the production of AGA. Acute and
chronic alcohol intake as well as gastroenteritis are not
uncommon, and so this could explain both the high
prevalence of AGA positivity in healthy subjects and the
lack of clinical relevance of AGAs in both the healthy
subjects and IBS patients.
Small-intestine endocrine cells in IBS and CD
Abnormalities in the densities of the various types of
endocrine cells in the small intestine have been reported
in both IBS and CD (Table 2 and Figs. 1, 2 and 3) [60–78],
and these abnormalities are considered to play an import-
ant role in the symptom development in both of these
Table 1 The consumption of rice in some Asian countries kg/
person/year
Time
period
Countries
Japan Thailand South Korea North Korea
1970–72 89 152 119 82
1999–2001 59 109 88 78
Data from [Hossain M. Food and Agriculture Organization of the United
Nation. 2004. www.fao.org/rice2004/en/e-001.htm]
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diseases [63, 79–81]. The pattern of changes in the dens-
ities of small-intestine endocrine cells in patients with CD
is quite different from that in IBS and postinfectious IBS
(PI-IBS).
Patients with both CD and IBS
It is not uncommon for patients with CD who consume
a gluten-free diet (GFD) and suffer from IBS symptoms
to present at the clinic. Reportedly 20–23.3 % of treated
CD patients fulfill the symptom-based Rome criteria for
IBS [82, 83]. A meta-analysis found that the pooled
prevalence of IBS symptoms in patients with treated CD
was 38 % [84]. Despite adhering to a GFD, patients with
CD who exhibit IBS symptoms have a reduced quality of
life as compared with those who do not [82, 83, 85]. It is
possible that CD and IBS coexist in some patients [86];
however, it is more likely that the inflammation in CD
does not subside completely in some patients after im-
plementation of a GFD, and a low-grade inflammation
[82] similar to that seen in PI-IBS may exist [36]. This
assumption is supported by certain observations in other
inflammatory bowel diseases such as ulcerative colitis
and Crohn’s disease, whereby 33–46 % of those with
ulcerative colitis and 42–60 % of those with Crohn’s
disease exhibit IBS symptoms during remission periods
[87–91]. Fecal calprotectin is significantly elevated in
ulcerative colitis and Crohn’s disease patients with IBS in
remission, compared to those without IBS-type symp-
toms, indicating the presence of occult inflammation [90].
IBS and NCGS
NCGS
NCGS receives widespread interest from the general
public and mass media, and is often confused with the
popular assumptions and speculations that the high
carbohydrate content of wheat is responsible for nega-
tive health aspects such as obesity [92]. The situation is
exacerbated by celebrities propagating these speculations
as a means of losing weight. The concept of NCGS was
first introduced in 1978 with a case report of a patient
with abdominal pain and diarrhea who exhibited no
abnormalities on small-intestine biopsy samples, whose
symptoms improved when they changed to a GFD [93].
A study of eight adult females with abdominal pain, diar-
rhea, and small-intestine biopsy findings with no signifi-
cant changes published in 1980 found that symptoms
were relieved when the patients adhered to a GFD, and
returned after a gluten challenge [94]. Similar results
have been reported in patients with nonceliac IBS-like
symptoms [95–97]. The withdrawal of wheat products
was found to improve these symptoms in double-blind
randomized, placebo-controlled studies involving pa-
tients with IBS-like symptoms [98, 99].
Whereas some studies involving experimental animals
and humans have revealed that exposure to gluten induces
intestinal low-grade inflammation, proliferation of periph-
eral blood monocytes, and enhancement of cytokine pro-
duction [96, 100–102], others were unable to find any
gluten-induced inflammation in NCGS [103]. Similar dis-
crepancies have been reported regarding small-intestine
permeability [96, 99, 104].
Is gluten responsible for NCGS?
As pointed out by Nijeboer et al. [105], in studies show-
ing an effect on symptoms in NCGS patients, that effect
was actually attributable to withdrawal of wheat rather
than gluten [96, 98, 99]. A placebo-controlled, crossover
study involving patients with IBS-like symptoms who
were on a self-imposed GFD [106] found that the
gastrointestinal symptoms consistently and signifi-
cantly improved during a reduced intake of ferment-
able oligosaccharides, disaccharides, monosaccharides,
and polyols (FODMAPs), and these symptoms were
not worsened by either a low- or high-dose challenge
with gluten. Moreover, in a study involving adults who
believed that they had NCGS, 24 % had uncontrolled
symptoms despite consuming a GFD, 27 % did not
strictly follow a GFD, and 65 % avoided other foods
that contained high levels of FODMAPs as additional
symptom triggers [107]. The findings of this study
lend further support to the notion that the gluten in
wheat is not the trigger of NCGS symptoms. However, in
a recent randomized, double-blind, placebo-controlled,
cross-over study on adults without CD or WA who be-
lieve that they suffer from NCGS showed that intake of
small amounts of gluten increase the intestinal and extra-
intestinal symptoms significantly [108].
Together these results indicate that it is not clear that
gluten is responsible for triggering NCGS symptoms; in-
stead, it appears that it is the carbohydrate content
(fructans and galactans) in the wheat that triggers these
symptoms. Indigestible and poorly absorbed short-chain
carbohydrates with chains containing up to ten sugars
(which are collectively called FODMAPs) occur in a wide
range of foods, including wheat, rye, vegetables, fruits, and
legumes [109]. These carbohydrates exert osmotic effects
Table 2 Patterns of changes in the densities of small-intestinal
endocrine cells in irritable bowel syndrome (IBS), celiac disease,
and postinfectious IBS (PI-IBS)
Endocrine cell type IBS Celiac disease PI-IBS
Secretin Decreased Decreased Unknown
Cholecystokinin (CCK) Decreased Increased Increased
Gastric inhibitory
peptide (GIP)
Decreased Increased Unknown
Serotonin Unchanged Increased Unchanged
Somatostatin Decreased Increased Unknown
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in the large intestinal lumen, resulting in an increased
water content. They are also fermented rapidly by
intestinal bacteria, with consequent gas production
[109–111]. Several studies, including some randomized,
placebo-controlled studies, have shown that FODMAPS
trigger gastrointestinal symptoms in IBS, and that a
low-FODMAPs diet reduces symptom severity and im-
proves the patient’s quality of life [112–119].
It is noteworthy that initiation of GFD without dietetic
supervision or education can cause inadequacies of nu-
trient intake including fiber, thiamin, folate, vitamin A,
magnesium, iron, and calcium [120]. Furthermore, it is
difficult [121] and more expensive to follow a GFD.
A
B
C
Fig. 1 Secretin cells in the duodenum of (a) a healthy subject, (b) a
patient with celiac disease (CD), and (c) a patient with irritable
bowel syndrome (IBS)
A
B
C
Fig. 2 Duodenal cholecystokinin cells in (a) a healthy subject, a
patient with CD (b), and (c) a patient with IBS
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Connection between IBS and NCGS
The definition of NCGS [28] coincides with that of IBS:
they have the same gastrointestinal and extragastroin-
testinal symptoms. A point of difference may be that
NCGS patients’ symptoms improve on withdrawal of
gluten and return with gluten ingestion. However, it is
not clear that gluten triggers the symptoms in NCGS
patients; rather, there is compelling evidence that they
are triggered by the fructan and galactan carbohydrate
components, which are FODMAPs [106]. Furthermore,
a considerable number of patients with NCGS experi-
ence no improvement of symptoms despite consuming a
GFD, and a large number appear to avoid other food
items that contain high levels of FODMAPs in addition
to consuming a GFD [107]. It is possible that the fre-
quency of IgG/IgA AGA is higher and the association
with human leukocyte antigens (HLA) DQ2 and DQ8 is
stronger in these patients [98]. As mentioned above,
confirmation of AGA positivity is not a specific test,
since a considerable number of healthy individuals are
positive for this antibody and HLA DQ2 and DQ8 are
common in healthy population.
The fructan contents in gluten-free bread (mostly
made of rice/corn), bread made from white wheat flour,
and bread made from spelt flour are 0.19 g/100 g,
0.68 g/100 g [6], and 0.14 g/100 g, respectively. In
addition, spelt flour contains 16 % less protein (mostly
gluten) compared to wheat [122]. Given the likelihood
that it is the carbohydrate components of wheat that
trigger symptoms in NCGS, spelt products would be a
better alternative to wheat than a GFD, which is widely
used by IBS patients [113, 114].
The following two statements from the research
groups of Murray and Sanders should be emphasized in
the ongoing debate regarding NCGS:
“Symptoms, symptom complexes, and symptom
characteristics are rarely, if ever diagnostic” [100]
and
“We believe that further work is required in what we
perceive as the research fertile crescent of gluten
sensitivity! Only then can we better inform practicing
clinicians on how to manage this group of patients” [86].
Conclusions
CD patients experience gastrointestinal symptoms simi-
lar to those seen in IBS patients, and are thus at risk of
being misdiagnosed as having IBS. Therefore, CD should
be excluded in IBS patients, regardless of the subtype. A
considerable proportion (20–37 %) of CD patients suffer
from IBS symptoms despite adherence to a GFD. It is
likely that the inflammation caused by gluten intake does
not completely subside in some CD patients, similar to
what is seen in inflammatory bowel diseases, whereby a
considerable number of patients exhibit IBS symptoms
in the remission phase.
It is not clear that gluten triggers the symptoms in
NCGS, but there is compelling evidence that carbohy-
drates (fructans and galactans) in the wheat does. Patients
A
B
C
Fig. 3 Gastric inhibitory polypeptide (GIP)-immunoreactive cells in
(a) a healthy subject, (b) a patient with CD, and (c) a patient with IBS
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with NCGS exhibit the same gastrointestinal and extragas-
trointestinal symptoms as those with IBS. Withdrawal of
wheat products reduces the symptom severity and im-
proves the quality of life in both NCGS and IBS patients.
Furthermore, there are no specific blood tests or radio-
logical or endoscopic examinations that are diagnostic for
either NCGS or IBS. It is likely that NCGS patients consti-
tute a group of IBS patients who are self-diagnosed and
have self-treated by adhering to a GFD.
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